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Abstract: Some random mutations can confer a selective advantage to a hematopoietic stem cell. As a
result, mutated hematopoietic stem cells can give rise to a significant proportion of mutated clones of
blood cells. This event is known as “clonal hematopoiesis.” Clonal hematopoiesis is closely associated
with age, and carriers show an increased risk of developing blood cancers. Clonal hematopoiesis of
indeterminate potential is defined by the presence of clones carrying a mutation associated with a
blood neoplasm without obvious hematological malignancies. Unexpectedly, in recent years, it has
emerged that clonal hematopoiesis of indeterminate potential carriers also have an increased risk
of developing cardiovascular disease. Mechanisms linking clonal hematopoiesis of indeterminate
potential to cardiovascular disease are only partially known. Findings in animal models indicate that
clonal hematopoiesis of indeterminate potential-related mutations amplify inflammatory responses.
Consistently, clinical studies have revealed that clonal hematopoiesis of indeterminate potential
carriers display increased levels of inflammatory markers. In this review, we describe progress in
our understanding of clonal hematopoiesis in the context of cancer, and we discuss the most recent
findings linking clonal hematopoiesis of indeterminate potential and cardiovascular diseases.
Keywords: clonal hematopoiesis of indeterminate potential; driver mutation; DNMT3A; TET2;
atherosclerosis; coronary heart disease
1. Introduction
A growing body of evidence is pointing at clonal hematopoiesis of indeterminate potential (CHIP),
defined as “the presence of clones in the absence of overt oncologic disease”, as a novel risk factor
linked to the development of hematological cancers or cardiovascular diseases later in life (for a
comprehensive view on the field, see [1]).
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Our review discusses the definitions and significance of clonal hematopoiesis (CH) and the
specific characteristics of CHIP, helps orientate the non-oncology expert to the jargon of this new
interdisciplinary field and aims to underscore the links between CHIP, malignancy risk and the
surprising risk in developing cardiovascular disease (CVD). Furthermore, based on the most recent
knowledge in the field, it discusses a few potential methods to combat and eventually mitigate the
pathogenic potential of mutated clones.
To fulfill the aims of our manuscript, we performed a systematic review following the preferred
reporting items for systematic reviews and meta-analyses (PRISMA) amendment to the quality of
reporting of meta-analyses (QUOROM) statement. The search strategy was performed between
October 2019 and May 2020. The terms searched were (clonal hematopoiesis) AND (myocardial
OR cardiovascular OR valvular OR thrombus OR heart failure OR infarction OR atherosclerosis OR
coronary). Only articles published in English and peer-reviewed journals were selected. The search
was carried out on PubMed, Biomed Central, Google Scholar, and Cochrane Library. The inclusion
criteria were observational studies focused on CHIP and its association with any type of cardiovascular
disease. We gave preferences to citations within the past five years; studies published before the first
study about CHIP were excluded. A total of 135 records were screened. For all articles, abstracts were
reviewed, and the full reference list was analyzed. All the authors agreed on the final number of
studies included.
2. Age-Related Clonal Hematopoiesis and Cancer
The first association between the presence of clonal expansion and cancer dates back to 1976 when
Peter Nowell proposed that cancer could arise from a single cell, and stated that tumor progression
might result from acquired genetic variability within the original clone, allowing sequential selection of
more aggressive sub-lines [2,3]. Consistent with that, Stratton and collaborators, in 2009, defined cancer
development as analogous to the Darwinian evolution process: both of them are characterized by the
continuous acquisition of heritable genetic variation and driven by natural selection acting on the
resultant phenotypic diversity [4]. Moreover, according to the definition by Cooper and collaborators [5],
clones are identical cells within a cellular population; consequently, clonality refers to a uniform
population of cells that could be either wild-type or mutant and eventually malignant. The concept of
clonality, although historically referring to myeloid and lymphoid neoplasms, could also be applied
to normal hematopoiesis. In this regard, clonality in normal hematopoiesis has been elegantly
demonstrated [6], also highlighting the fact that hematopoietic stem/progenitor cells’ (HSPC) clonality
can be restored and reactivated [6].
Most somatic mutations occurring in the DNA sequence of a cell allow limited abnormal growth
potential and have no effects on cell proliferation, or cause limited benign growth; occasionally, a single
cell acquires a set of sufficiently advantageous mutations that allow it to proliferate autonomously,
invade tissues and metastasize. Somatic mutations may be defined either as “driver,” i.e., those who
contribute to clonal expansion, or “passenger,” i.e., those who do not. However, either mutation could
indicate the presence of a clone; although driver mutations lead to clonal expansion, they may not
necessarily be associated with malignant neoplasia. It might, therefore, be assumed that every somatic
mutation occurring in cancer genes, able to give a growth advantage to the cell carrying the mutation,
represents a driver mutation (for further details, see Table 1).
It has been estimated that epithelial cancers, such as breast, colorectal, or prostate cancer,
require several driver mutations (see Table 1), whereas cancers of the hematological system may need
fewer [7]. Well-defined cancers’ precursor states, such as adenomatous colon polyps or dysplasia of the
uterus or cervix, have illuminated the multistep process of oncogenesis. Hematological malignancies’
precursor states, in contrast, do not have any anatomical correlates: blood cell counts and bone marrow
morphology in a hematological precursor state may be, in fact, entirely normal; these states being
instead defined by markers of clonality like the recently described clonal hematopoiesis [8–10].
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Table 1. Driver and passenger mutation, clone and clonality definitions [4,5].
Clone Cells that share identical genomes within a cellular population.
Clonality
Historically refers to myeloid and lymphoid neoplasms; today denotes a
uniform population of cells that could be either wild-type or mutant and
eventually malignant.
Driver mutation
Driver mutations confer a growth advantage to the cells carrying them,
and are positively selected during the evolution of cancer. They occur in
a particular set of genes called “cancer genes”, and are often the primary
causative agent of cancer.
Passenger mutation
Passenger mutations are inert somatic mutations. They are unable to
confer clonal growth advantages, and therefore do not lead to cancer
development. Nevertheless, passenger mutations are usually found in
cancer cells’ genomes because when a driver mutation occurs, even a
passenger mutation is carried together with the clonal expansion.
Blood stem cells acquire random somatic mutations with each cell division over time. Most of
these mutations have little or no effect on normal cell physiology, but eventually, some of them could
provide a selective advantage to the hematopoietic cell in which they occur. The result is a clonal
expansion in the peripheral blood since the mutated stem cells maintain the ability to differentiate into
granulocytes, monocytes, and lymphocytes [11–17].
CHIP has been recently defined by Steensma as a process in which somatic mutations in
leukemia-associated driver genes result in the expansion of a clone of bone marrow and peripheral
blood cells [9]; it is, therefore, a clonal expansion of hematopoietic cells with a somatic mutation in the
presence of otherwise normal white blood cells [11]. More specifically, CHIP refers to a CH with a
variant allele fraction of at least 2% or higher in blood or bone marrow samples without a diagnosis
of other hematological conditions, thus distinguishing this particular condition from pre-leukemic
states such as myelodysplastic syndrome (MDS). Other main features of CHIP include the absence
of morphological variation in the blood cells as well as diagnostic criteria for symptoms currently
associated with hematological cancer (for example, gammopathy) [13,14]. The prevalence of CHIP
varies with age, ranging from less than 1% in those younger than 40 years, to more than 15% in those
90 years and older [12,18,19]. Generally, the clonal mosaicism for a large chromosomal abnormality,
reflecting the expansion of a specific cell clone, appears to arise in approximately 2% of the elderly
population [20]. Criteria for CHIP definition are summarized in Table 2.
Table 2. Diagnostic criteria for clonal hematopoiesis of indeterminate potential (CHIP) [12,18].
Clonal hematopoiesis of
indeterminate potential (CHIP)
Any clonal expansion of hematopoietic cells in a
non-hematologic patient.
It is characterized by
- Absence of morphological variation in the blood cells, denoting
morphological evidence of a hematological neoplasm;
- Presence of a somatic mutation associated with hematological
neoplasia, at a variant allele fraction of at least 2% in the
peripheral blood;
- Absence of diagnostic criteria for symptoms currently
associated with hematological cancer (i.e., monoclonal
gammopathy of undetermined significance or monoclonal
B-cell lymphocytosis).
The most commonly mutated genes in CHIP are the DNA methyltransferase 3A (DNMT3A),
the DNA demethylase TET2, and the transcription regulator ASXL1. Mutations in these three genes are
commonly associated with MDS and acute myeloid leukemia (AML), providing a selective advantage
to the hematopoietic stem cell in which they occur [18–22]. TET2 mutations have also been described
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as leukemia-associated events that appear to be present in up to 25% of patients with myeloid
neoplasm [23]. Moreover, DNA methylation patterns change with age, and alterations in the DNA
methylation process have recently been associated with atherosclerosis as well as with MDS and its
drug responsiveness [24,25]. Methylation of the promoter region is frequently used by the cell to
inactivate gene expression, and DNA methyltransferase inhibitors can induce the re-expression of
previously methylated silenced gene products [26]. Mutations in the ASXL1 gene are associated with
MDS and chronic myelomonocytic leukemia [27–29]. More recently, Shlush and collaborators reported
that DNMT3A mutations are common in pre-leukemic stem cells [30]. In 2014, three independent
groups reported analysis of DNA exome datasets and documented age-dependent mutations in
genes associated with hematological cancers. Out of more than 70 different genes being identified,
the most frequently mutated were DNMT3A, TET2, ASXL1, TP53, JAK2, SF3B1, CBL, SRSF2, PPM1D,
and BCOR [3,19,31]. These mutations were common, showing, for example, an increase in red cell
width (which could be a marker of perturbation of hematopoiesis due to the expanded clone) [31].
Genovese and collaborators analyzed whole-exome sequences of the DNA in peripheral blood cells
analyzed whole-exome for cancer or other hematological phenotypes. The vast majority of mutations
were found in four genes, DNMT3A, TET2, ASXL1 and PPM1D. All of these mutations also occurred
with a low allelic fraction, therefore confirming that they were somatic mutations. Of note, CHIP with
somatic mutations was detected in 10% of the elderly study participants, with increasing frequency
with age; in the tested cohort, up to 7 years after DNA sampling, approximately 42% of subjects who
displayed clonality at the time of sampling developed hematological cancer. Importantly, only 10% of
the studied population displayed CHIP, and the absolute risk of conversion from clonal hematopoiesis
to hematological cancer was found to be as low as 1.0% per year.
Therefore, this study suggests that, although the presence of clones highly correlates with, and is
a strong risk factor for these cancers, whole-genome sequencing of blood samples, for screening
purposes, would represent a premature and useless approach.
In the next paragraphs, we will present emerging evidence from epidemiologic and clinical studies
of an association between CHIP and cardiovascular disease (CVD). This finding is not surprising since
there is compelling evidence showing that cancer and CVD share biological mechanisms underlying
their pathogenesis [32]. Inflammation participates in the pathogenesis of both cancer and CVD, and it
is involved in the initiation, the progression, and the complication of both malignant tumors and
atherosclerotic plaques [33]. Regulation of the inflammatory signaling pathways has resulted in an
innovative strategy in the treatment of cancers, as well as in a reduction in the risk of cardiovascular
events. Furthermore, the incidences of both cancer and CVDs increase with advancing age [34,35].
Cardiovascular disease is the leading cause of death in the elderly, but almost 60% of elderly patients
with atherosclerotic CVD have either no conventional risk factor or just one risk factor [36–38].
3. CHIP Is Associated with Cardiovascular Diseases
Jaiswal et al. [31] were the first to report that the presence of CHIP-linked mutations leads to a 40%
increase in all-cause mortality, which is, in turn, linked to an increased risk of coronary heart disease
and ischemic stroke. They analyzed the whole-exome sequencing data from the peripheral blood
DNA of 17,182 subjects, unselected for hematological cancers, in 22 cohorts of three different consortia.
Their study confirmed that the most frequent mutated genes in CHIP are DNMT3A, TET2, and ASXL1,
and revealed an increased risk of mortality from cardiovascular disease (40%) in comparison to the risk
of dying from hematological cancers (4%) in patients carrying a mutation in the CHIP genes. Moreover,
the comparison between subjects carrying one or more CHIP mutations and non-carriers showed
no significant differences in hematological values except for red cell distribution width. To study
more in-depth the relationships between CVD and CHIP, in a later study, Jaiswal et al. carried out
whole-exome sequencing on blood samples obtained from four case-control studies consisting of
4726 individuals with coronary heart disease and 3529 control individuals (matched on the basis of
age, sex, type 2 diabetes status, smoking history in the prospective cohorts; for more details, see [14]).
J. Clin. Med. 2020, 9, 2480 5 of 20
Interestingly, CHIP carriers had a risk of coronary heart disease that was 1.9 times higher than
non-carriers, which was comparable with what was found in the prior study. In two retrospective
case-control studies for the evaluation of early-onset myocardial infarction, subjects with CHIP had a
risk of myocardial infarction that was 4.0 times higher in comparison to non-carriers. In these cohorts,
mutations in DNMT3A, TET2, ASXL1, and JAK2 were each individually linked to coronary heart
disease [14]. These data demonstrate not only that CHIP is an age-related premalignant condition,
but that it is also associated with an overall increased mortality rate as well as an increased risk of
cardio-metabolic diseases. Importantly, coronary events increased with clone size, and there was
also a dose–response relationship between clone size and atherosclerosis based on artery calcification
imaging [14]. In this regard, CHIP subjects without coronary heart disease, but carrying a variant allele
fraction of a least 10%, had 12 times the risk of having a high coronary-artery calcification score as
did non-carriers, whereas participants with a variant allele fraction of less than 10% had no increased
risk [14].
Dorsheimer et al. [22] further extended these observations: they tested for the presence of CHIP
mutations in archived bone marrow DNA samples from 200 patients with chronic heart failure (HF)
caused by ischemic pathology, enrolled in different clinical trials evaluating autologous bone marrow
treatment. This undertaking yielded several significant findings: firstly, in this population of survivors
of acute myocardial infarction, the prevalence of CHIP mutations increased with age, in agreement
with the study by Jaiswal et al. [14], since the somatic mutations most frequently occurred in DNMT3A
and TET2 genes, and were detected both in bone marrow and peripheral blood samples [22]. Secondly,
carriers of CHIP had a marked increase in the risk of death from HF [22], also in accord with prior
studies [31]. Kaplan–Meier survival plots, related to patients carrying either DNMT3A or TET2
mutations, clearly documented a worse long-term clinical outcome, both in terms of re-hospitalization
due to ischemic events and death [22]. Two commentaries have highlighted the novelty and the
importance of Dorsheimer’s study [39,40], since most of the fatalities among patients with CHIP
resulted, in fact, from worsening HF and not atherothrombotic events [22].
Moreover, in this group, CHIP carriers also had an increase in the number of hospitalizations for
HF [22]. These observations, therefore, support the involvement of CHIP, not only in the pathogenesis
of myocardial infarction and stroke, as previously shown [31,39,41], but also in HF. The resulting
association of mutant clone size and risk of death in this population could not be explained by CHIP
carriers holding a worse HF baseline risk, as measured by alterations in left ventricular ejection fraction,
known HF risk scores and serum levels of N-terminal pro-B type natriuretic peptide; thus, HF behaves
definitely as a “bona fide” cardiovascular complication of CHIP.
Recently, Mas-Peiro et al. [40] investigated the effect of the presence of CHIP on the clinical course
of aortic stenosis. The study enrolled 279 aortic stenosis patients of which 93 (33%) had mutations
in DNMT3A or TET2, the two most common CHIP-driver genes. Ageing renders aortic valve cusps
impaired in its functions, with different degrees of sclerosis which can further progress to calcific aortic
valve stenosis [42]. In the patients studied by Mas-Peiro et al., CHIP mutations were associated with
worse outcomes, including increased mortality after valve replacement during a median 8-month
follow-up. The patients with DNMT3A or TET2 mutations displayed a three-fold increase in mortality
compared with non-CHIP carriers. Interestingly, CHIP mutations in aortic stenosis patients were
not associated with an increase in pro-inflammatory circulating cytokines, but were linked to an
inflammatory phenotype in specific immune cell subsets. Specifically, DNMT3A mutation carriers
displayed an increase in the Th17 to regulatory T-cell (Tregs) ratio, while TET2 mutations were
associated with an increase in the non-classical monocytes. In addition, the same group performed
a single-cell RNA sequencing analysis which revealed that the circulating monocytes of patients
with aortic stenosis with CHIP driven by DNMT3A or TET2, or HF patients carrying DNMT3A
mutations, have an increased expression of IL-1β IL-6 receptor, NLRP3 and CD163, a receptor involved
in macrophage activation syndrome [43]. A list of all epidemiological and clinical studies on CHIP and
CVD is provided in Table 3.
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Table 3. List of studies investigating the link between CHIP and CVD in patients and animal models.
BM, bone marrow; CHD, coronary heart disease; CVD, cardiovascular disease; HF, heart failure; HF/HC,
high fat/high cholesterol; HSPC, hematopoietic stem/progenitor cells; LAD, left anterior descending
artery; ldlr, low-density lipoprotein receptor; TAC, transverse aortic constriction; TAVI, transcatheter
aortic valve implantation.
EPIDEMIOLOGICAL/
CLINICAL STUDIES
STUDY/REFERENCE C.H.I.P. STATUS STUDY COHORT MAIN FINDINGS
Jaiswal et al., 2014
Variants in 160 genes
associated with hematological
neoplasms.
17,182 subjects without
hematological alterations.
CHIP is associated with
increase in the risk of incident
CHD and ischemic stroke.
TET2, DNMT3A and ASXL1
mutations individually
associated with CHD and
ischemic stroke.
Jaywalk et al., 2017 Variants in 74 genes associatedwith hematological neoplasms.
4726 subjects with CHD and
3529 controls.
CHIP is associated with
increased risk of CHD and
early-onset MI.
TET2, DNMT3, ASXL1 and
JAK2 mutations individually
associated with CHD and
early-onset MI.
Dorsheimer et al., 2019 Variants in 56 genes associatedwith hematological neoplasms.
200 patients with HF following
MI.
DNMT3A and TET2 carriers
have increased death or HF
re-hospitalization during a
median follow-up of 4.4 years.
Mas-Peiro et al., 2019 Variants in TET2 andDNMT3A.
279 patients undergoing TAVI
for severe aortic valve stenosis.
Patients with CHIP have
increased all-cause mortality
following successful TAVI
during median follow-up of 9
months.
Bick et al., 2020 Variants in TET2 andDNMT3A.
35,416 subjects from UK
Biobank without prevalent
CVD.
CHIP is associated with
increased risk of CVD.
CHIP carriers with protective
IL-6R variants have decreased
CVD risk.
Abplanalp et al., 2020 Variants in TET2 andDNMT3A.
8 patients with severe aortic
valve stenosis and 6 patients
with HF.
CHIP carriers’ monocytes
display a pro-inflammatory
expression profile.
Wolach et al., 2018 JAK2VF variant 10,893 subjects withoutmyeloid disorders.
JAK2VF mutations associated
with increased risk of venous
thrombosis.
ANIMAL MODEL
STUDIES
STUDY C.H.I.P. GENES ANIMAL MODELS MAIN FINDINGS
Fuster et al., 2017 Tet2
Competitive BM transplant
with Tet2 -/- cells in irradiated
ldlr -/- mice.
HF/HC-induced
atherosclerosis.
Tet2 deficiency increases
atherosclerotic plaque size and
total number of macrophages
in the intima of the vascular
wall.
Tet2-deficient macrophages
show increase in NLRP3
inflammasome-mediated
IL-1β secretion.
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Table 3. Cont.
ANIMAL MODEL
STUDIES
STUDY C.H.I.P. GENES ANIMAL MODELS MAIN FINDINGS
Jaiswal et al., 2017 Tet2
Irradiated ldlr -/- mice
transplanted with Tet2 -/+ or
Tet2 -/- BM cells.
HF/HC-induced
atherosclerosis.
Tet2 deficiency increases
atherosclerotic lesions in the
aortic root and aorta.
Tet2-deficient macrophages
express more
pro-inflammatory chemokines
and cytokines.
Sano et al., 2018 Tet2
Competitive BM transplant
with Tet2 -/- cells in irradiated
mice or conditional
myeloid-restricted inactivation
of Tet2.
HF alternatively induced by
TAC or LAD ligation.
Tet2 deficiency worsens
cardiac remodeling and
function, and increases IL-1β
expression.
Wang et al., 2020 Tet2
Non-preconditioned mice
transplanted with Tet2 -/+ or
Tet2 -/- BM cells.
Tet2 deficiency causes
age-related hypertrophy and
fibrosis.
Donor-derived macrophages
in the heart have increased
inflammatory features.
Sano et al., 2018 Tet2 and Dnmt3a
Irradiated mice transplanted
with Tet2 -/- or Dnmt3a -/-
CRISPR-edited HSPCs.
Angiotensin-II-induced HF.
Tet2/Dnmt3a mutations cause
increased cardiac hypertrophy
and fibrosis, and reduction in
cardiac function.
Wang et al., 2018 Jak2
Irradiated ldlr -/- mice
transplanted with
Jak2VF-expressing BM cells.
HF/HC-induced
atherosclerosis.
Jak2VF mutation increases
early and advanced
atherosclerosis, promoting
neutrophil infiltration and
plaque instability.
Jak2VF macrophages show
increased pro-inflammatory
cytokines and chemokines.
Sano et al., 2019 Jak2
Irradiated mice transplanted
with HSPCs expressing Jak2VF.
HF alternatively induced by
TAC or LAD ligation.
Jak2VF mutation causes HF
associated with increased
expression of IL-6 and IL-1β.
CRISPR, clustered regularly interspaced short palindromic repeats.
4. Mechanisms by which CHIP Increases Cardiovascular Risk
Epidemiological and clinical studies that have identified the association between CHIP and
CVD do not provide information on whether a causal link exists between CHIP and CVD. Similarly,
these studies did not explore potential mechanisms underlying the increased risk of CVD in CHIP
carriers. For this reason, animal models have been used to investigate whether, and through which
mechanisms, CHIP is causally linked to CVD (Table 3).
These experimental results are discussed in the next paragraphs. Table 3 is a synopsis of the
animal and human studies that support the hypothesis of CHIP–driven increase in CVD risk.
4.1. TET2 and DNMT3A
Experiments in genetically engineered mice have shown that CHIP contributes actively to
cardiovascular complications. In 2017, Fuster and collaborators focused on TET2, the first gene shown
to exhibit a somatic mutation in CHIP [44], known for its involvement in hematopoietic stem cell
renewal and cancer [45,46], but so far not associated with CVD development. Mice that lack Tet2 have
accelerated atherosclerosis and a heightened tendency to develop left ventricular dysfunction [44].
Authors observed a clonal expansion into all blood cell lineages, and, regardless the type of diet, a
profound effect on diet-induced atherosclerosis in Tet2 KO mice that displayed plaques in the aortic root
which were 60% larger than those in wild-type controls. This finding was paralleled with an increase
in the number of macrophages in the intima of the vascular wall, thus suggesting that Tet2-deficient
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hematopoietic cells accelerate atherosclerosis by means of macrophages with enhanced atherogenic
activity, probably due to an Interleukin-1ß (IL-1ß)-mediated mechanism. Consistent with the study of
Fuster and collaborators [44], Jaiswal and collaborators [14] showed that mice with either heterozygous
or homozygous loss of Tet2 developed aortic root lesions that were 50–70% larger than those in control
mice at early time points, while the involved area was also approximately two-fold larger in the
descending aorta at later time points.
One year later, Sano et al. [47] studied the effect of mutations in TET2 or DNMT3A in HF,
and reported that, in two experimental mouse models of HF, loss of Tet2 in bone marrow cells led to
reduced left ventricle ejection fraction and increased cardiac fibrosis and remodeling. The same group,
in 2018 [48], found that deletion of either Tet2 or Dnmt3A in bone marrow caused increased cardiac
hypertrophy and fibrosis and a reduction in cardiac function in mice with angiotensin-II-induced HF,
suggesting that the reduced survival rate seen in patients with TET2 or DNMT3A mutations is causally
related to altered immune cell function in the myocardium [39,40]. Recently, Sano et al. confirmed the
casual relationship between Tet2-mutated clone expansion and the development of HF in non-irradiated
mice that have not been preconditioned by a myeloablative strategy [49]. In this study, mice receiving
Tet2-deficient bone marrow cells spontaneously developed age-related cardiac hypertrophy and fibrosis
that were associated with an increased inflammatory signature in donor-derived Tet2-deficient interstitial
macrophages [49]. This observation could be explained by the fact that, in murine macrophages and
dendritic cells, Tet2 represses the transcription of pro-inflammatory molecules such as IL-6, a known
pro-atherogenic mediator (even if this IL-6-driven atherogenic effect has been reported to be independent,
at least in part, of the well-known enzymatic role of TET2 [39,40]).
Although findings from clinical studies are in agreement with the mechanistic data obtained
in animal models, some evidence seems to contrast with a pro-atherosclerotic role of TET2.
Kaasinen et al. [50] recently investigated the effect of TET2 germline mutations in six carriers,
representative of three different inactivating mutations, without observing clinical evidence of increased
atherosclerosis in those carriers. Macrophages of subjects carrying germinal TET2 mutations did not
display increased secretion of IL-1β or IL-8 (50). These findings, in contrast to previous studies, may
indicate that TET2 loss may be of limited importance with regard to atherosclerosis. However, it must
be considered that germinal TET2 loss, compared to somatic mutations involving only a relatively
small fraction of cells, has a wider impact and it is likely to result in the alteration of several processes
which could possibly compensate for pro-atherogenic effects. For instance, Kaasinen and collaborators
observed an increased expression of chemokine receptor type 4 (CXCR4) in individuals with germinal
TET2 mutation that, since CXCR4 exerts an anti-atherosclerotic effect by preserving vascular function
in arteries [50], may counterbalance the pro-atherosclerotic effect. In a recent paper, Doring and
collaborators [51] demonstrated that CXCR4, the receptor of CXCL12 (whose expression and plasma
levels were previously associated with coronary artery disease [52,53]), was able to confer cell-specific
athero-protective effects preserving endothelial function in mice.
In contrast, reduced CXCR4 expression was associated with CAD risk in humans, indicating
the complex effects of this ligand-receptor axis in atherosclerosis and CAD. Importantly, TET2 loss
causes the deregulation of expression of several genes involved in stem cell renewal or differentiation
and cancer [54], and can also promote the accumulation of other mutations [55]. Among the genes
regulated by TET2 [56] and frequently co-mutated in Tet2 KO stem cells, there is NOTCH1 [56], a gene
known to play a significant role in modulating immune responses and inflammation [57], two factors
tightly linked to CVD [58,59].
4.2. JAK2 Mutations Promote Thrombotic Diseases and Increase Inflammation
JAK2 is a non-receptor tyrosine kinase associated with several cytokine receptors and is
critically involved in different processes such as erythropoiesis, atherosclerosis, endothelial cell
activation, and myocardium inflammation [60–64]. The JAK2V617F (JAK2VF) mutation is linked to
myeloproliferative neoplasms (MPN), and in these diseases, it is associated with thromboembolic
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complications, increased blood viscosity and platelet adhesion, as well as reduced venous blood
return [65]. In addition, Wolach et al. have shown that in MPN, JAK2VF promotes acute coronary events
and thrombosis by accelerating the formation of neutrophil extracellular traps (NET), components of
innate immunity [66]. Importantly, in this study, JAK2VF mutation was also associated with thrombosis
in subjects without MPN or other hematologic disorders [66]. Furthermore, Wang and collaborators
have shown that hematopoietic JAK2VF expression is associated with increased atherosclerosis, both in
its early and advanced stages, as it promotes neutrophil infiltration and plaque instability in a mouse
model of hypercholesterolemia [67]. In this model, JAK2VF mutation has also been associated with
defects in the functions of erythrocytes and macrophages, which cause increased erythrophagocytosis
and abnormal efferocytosis [67].
The role of JAK2 mutations in the context of CHIP has been explored by Sano and
collaborators, who found that in a murine model of HF, which shows no sign of MPN phenotype,
myeloid-directed Jak2VF expression generated circulating mutated myeloid cells, leading to an increase
in myocardial inflammation and HF through a signal transducer and activator of transcription (STAT)-1
phosphorylation-dependent mechanism [68]. Moreover, myeloid-restricted Jak2VF mutation was also
associated with increased expressions of IL-6 and IL-1β and an increased ability of macrophages to
migrate to the heart.
Collectively, these findings indicate that JAK2 hyper-activation can promote CVD by altering
hematopoiesis and then promoting thrombotic diseases. In addition, JAK2 mutations may favor CVD by
boosting innate immunity responses, and this may explain how JAK2-driven CHIP favors atherosclerosis
and HF (see Figure 1 for a comprehensive mechanistic view of CHIP and cardiovascular risk).
4.3. CHIP, The Chronic Inflammatory State and Ageing: One Culprit for Different Pathologies?
Evidence obtained in animal models shows that an increase in inflammation induced by
CHIP-related mutations, worsens both atherosclerosis and HF [20,21]. Recent data in humans confirmed
the inflammatory nature of atherosclerosis and the rationale of targeting inflammatory pathways as a
valuable therapeutic tool [69]. However, even more recent data demonstrated that not all the strategies
aimed to interfere with inflammatory pathways are effective in atherosclerosis [70]. The relationship
between CHIP and chronic inflammation (and subsequent heightened vascular risk) is reported: CHIP
causes an increase [71,72] in inflammatory responses and, at the same time, cells carrying CHIP mutations
have a fitness advantage under pro-inflammatory conditions [73]. An interesting clinical translation
of these findings is the recent observation that suggests a relationship between CHIP and HF [22,74].
Among prominent risk factors in HF genesis, age and systemic inflammation play a prominent role,
and the most commonly mutated CHIP-driver genes (TET2 and DNMT3A) are associated with poor
prognosis [22,31,39,74] in HF [22,74], even with different effects on the hematopoiesis driven by the two
mutated genes. It is conceivable that a relationship exists between CHIP, the inflammatory state that
worsens as we age [75], and the increased vascular risk in the elderly, with one factor influencing the other
and vice-versa [75]. Furthermore, old age is usually associated with higher levels of IL-6, IL-1 receptor
antagonist (IL-1ra), IL-18, C-reactive protein (CRP), fibrinogen, and soluble IL-6 receptor (sIL-6r) [75].
The latter study supports a tight correlation of inflammatory signals with CVD. However, we do not
yet have a clear-cut biomarker of “inflammaging”, because not all the known inflammatory markers
increase in older age [76]. Which comes first: cytokine or disease? The most recent data point towards
a heightened immune activation and sustained inflammatory state, as an “adjuvant” of the vascular
phenotype linked to the mature-age and elderly [76–78]. At the same time, CHIP could qualitatively
influence the “inflammatory pabulum” and increase pro-inflammatory cytokine secretion [1,76,77].
A recent paper by Bick et al. [78] seems to support this scenario, because the attenuation of IL-6 signaling,
caused by a genetic IL-6r variant, reduced cardiovascular risk in CHIP carriers. In addition, they
reported a modest increase in hs-CRP (high sensitivity C-reactive protein) in the univariate analysis
but not in the co-variate–adjusted analysis [78]. Moreover, data (not yet peer-reviewed) by the same
group [79] claim CHIP association with IL-6 and IL-β levels, but not with hs-CRP (in a wide analysis of
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32 cohorts, with 97,691 individuals and identifying 4229 CHIP cases). On the contrary, a very recent
study by Busque et al. [80] shows that high-sensitivity (hs)-CRP is significantly higher in subjects with
CHIP versus subjects without CHIP (analyzing, in total, 1887 subjects), supporting the hypothesis that
a link between inflammation and CHIP-linked increased risk of CVD pathogenesis exists in ageing
individuals. Despite these differences, taken together, these data confirm the association between
inflammation, CHIP and aging.
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Figure 1. Clonal hematopoiesis of indeterminate potential (CHIP) causes cardiovascular disease.
Mutations can confer a selective advantage to a hematopoietic stem cell (HSC) that leads to clonal
expansion of the mutated HSC, which can give rise to a significant proportion of clones of mutated
somatic blood cells. TET2 and JAK2 mutations preferentially involve myeloid cells. DNTM3A mutations
are present in somatic blood cells of both myeloid and lymphoid origin. Mutati ns in the genes TET2,
DNMT3A and JAK2 (in black) are associat d with increased cardiovascular risk in epide iological
studies, and they have been causally implicated in cardiovascular diseases in animal models. TET2 and
DNMT3A mutations (in grey italic) are enriched in aortic valve stenosis, but causality has not been
established yet (indicated with dashed lines). JAK2 (in grey italic) hyperactivation is associated with
thrombosis in CHIP patients; causality between JAK2 mutations and thrombotic diseases has been
established in an animal model of myeloproliferative neoplasm (MPN).
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Likely, CHIP mutation load increases pro-inflammatory cytokine release, fueling a feedback loop
in which several inflammatory molecules promote clonal expansions of mutated clones, which then
amplify dysregulated and unbalanced pro-inflammatory cytokine release. Importantly, CHIP mutations
involve myeloid cells, such as granulocytes, monocytes and NK cells, more frequently than B or T
cells [81,82]. In mice with ischemic HF, Tet2 loss-of-function mutations restricted to myeloid cells
are sufficient to worsen cardiac function [47]. Jak2VF mutations in myeloid progenitors give rise to
monocytes and neutrophils with increased inflammatory features, causing myocardial inflammation
and accelerated HF after ischemic injury [68]. Dntm3a mutations result in a less pronounced bias
towards myeloid cells [81,82]. However, mice transplanted with Dnmt3a-deficient HSCs, infused with
angiotensin III to cause cardiac dysfunction, have displayed increased macrophages infiltration and
increased transcription of markers of both innate and adaptive immune cells in the myocardium [48].
Data from animal models seem consistent with evidence from clinical trials showing that subjects
with TET2 mutations have more inflammatory non-classical monocytes, while those with DNMT3A
mutations have an increased an Th17/Tregs ratio [42]. Overall, these findings indicate that TET2
and JAK2 mutations preferentially increase inflammation mediated by innate immunity; otherwise,
DNTM3A mutations affect both myeloid and/or lymphoid cells.
5. Potential Strategies for Targeting High-Risk CHIP Mutations
Animal model studies have revealed some of the mechanisms by which CHIP mutations promote
CVD, paving the way for the development of possible therapeutic options to reduce CVD risk in
CHIP carriers. However, interventions aimed at reducing the risk associated with CHIP have not
been attempted in clinical settings, and whether this may translate into practice in the future is still
uncertain. In this section, we will discuss hypothetical approaches that could be examined as potential
interventions to mitigate the pathogenic potential of mutated clones.
5.1. Immune Therapy
CHIP mutations drive an increase in inflammatory responses; at the same time, cells carrying
CHIP mutations have a fitness advantage under pro-inflammatory conditions [47,48,50]. Hence,
targeting inflammation may mitigate the effects of CHIP, both by reducing clonal expansion and the
CHIP-dependent inflammation. In murine models of CHIP driven by Tet2, NLRP3 inhibitor MCC950
reduces IL-1β and atherosclerosis [44], and decreases fibrosis and hypertrophy following myocardial
infarction [47]. Cai and collaborators demonstrated that in Tet2-knockout mice (Tet2-KO), inflammatory
stress results in an increase in IL-6, and that, in turn, IL-6 produced by Tet2-deficient HSPCs promotes
clonal expansion. In these mice, inhibition of IL-6 downstream effectors SHP2-STAT3 reduced both IL-6
production and the clonal expansion of Tet2-KO HSPC [83]. Monoclonal antibodies against specific
cytokines such as IL-1β (canakinumab) and IL-6 (tocilizumab and clazakizumab) are already used in
clinical practice or being tested in clinical trials to treat diseases in which cytokines are abnormally
secreted [69,84,85]. Similarly, targeting inflammatory pathways mediated by IL-1β and IL-6 may
mitigate the deleterious effects of inflammation, possibly improving CVD outcomes in CHIP carriers.
5.2. JAK2 Inhibitors
Wolach and collaborators [66] demonstrated that, in a deep-vein-stenosis murine model, NET
formation and thrombosis are blunted by inhibition of Jak2 with ruxolitinib. In a very recent study in
rabbits fed a high-fat diet, ruxolitinib reduced the atherosclerosis induced in aorta by balloon injury [86].
Furthermore, it has been shown that the selective Jak2 inhibition with fedratinib reduces the formation
of atherosclerotic plaque in Apoe-/-mice [87]. Interestingly, Edelmann and collaborators [88] found
that in a mouse model of Jak2VF-positive chronic myeloproliferative neoplasia (CMN), Jak2 promotes
venous thrombosis by activating β1 and β2 integrins in leukocytes and, thus, inhibition of integrin
activation could prevent pathologic thrombus formation. Collectively, these findings suggest that
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inhibition of JAK2 or downstream integrins may alleviate thrombotic CVD in CHIP patients carrying
JAK2 mutations.
5.3. Vitamin C to Compensate for TET2 Function
In a mouse model of Tet2-dependent leukemia, treatment with vitamin C restored Tet2 activity
in HSPCs [89]. Similarly, in human leukemia cells, vitamin C suppresses proliferation and induces a
TET2-dependent gene signature [89]. Vitamin C as an adjunct to decitabine therapy in AML patients
can boost TET2 activity [90]. Furthermore, it has been reported that vitamin C treatment alone
induced clinical remission in a case of AML with mutations in TET2 and Wilms tumor protein 1 (WT1),
a transcription factor that recruits TET2 to DNA [91]. However, whether vitamin C might rescue TET2
activity in patients without AML is still unknown.
5.4. Glucose-Lowering Drugs
CHIP carriers display a 30% increased risk of type 2 diabetes [14], which is a risk factor for both
CVD and cancer [92]. However, it is not known yet whether CHIP promotes diabetes or whether the
two conditions increase independently with age. In diabetic mice, high glucose destabilizes the TET2
protein, while lowering glucose with metformin rescues TET2 activity [93]. This finding suggests that
high glucose may exacerbate the effect of TET2 mutations; on this basis, it could be hypothesized that a
tight control of glucose levels may mitigate CVD risk in patients carrying TET2-driven CHIP. Figure 2
shows a synopsis of potential therapeutic strategies aimed to tackle CHIP-linked cardiovascular disease.
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Figure 2. Potential strategies of targeting high-risk CHIP mutations. TET2 deficiency causes
the increased expression of IL-1β and IL-6, which in turn activates the Shp2/STAT-3 signaling
axis. Antibodies targeting IL-1β and IL-6, NLRP3 or STAT-3 inhibitors could mitigate the effect
of a CHIP-mediated inflammation response. High glucose levels destabilize the TET2 protein.
Lowering glucose by metformin may rescue TET2 activity. The mutagenic event that determines JAK2
hyperactivation is associated with thromboembolic events. JAK2 inhibitors (ruxolitinib or fedratinib)
or anti-integrin inhibitors may reduce atherothrombotic complications.
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6. Conclusions and Future Perspectives
CHIP is a common, and perhaps inevitable, consequence of ageing. Individuals carrying these
mutated clones are at increased risk, not only of developing hematological cancer, but also CVDs,
such as atherosclerosis, stroke, thrombosis and HF. Our understanding of causative mechanisms
linking CHIP to CVD is yet to be fully elucidated, and currently, no therapies are available that can
reduce the risk of cancer or CVD for CHIP carriers.
The link between CVD and CHIP could be ascribed to inflammation, and it could be mediated by
an inflammatory signaling pathway. A positive feedback mechanism of regulation and progression
of the cross-talk between CHIP and CVD has been hypothesized: CHIP might induce inflammation
and accelerate atherosclerosis, which in turn could further stimulate the expansion of mutated
HSPC clones and their progeny, and further induce inflammatory responses and CVD progression.
Clonal hematopoiesis may therefore contribute to the progression of CVD, by driving the release of
several cytokines or augmenting the senescence of blood stem cells by altering the function of epigenetic
modifiers. On the other hand, it should also be considered that the expansion of mutated HSC clones,
characteristic of CHIP, may be boosted by classic cardiovascular risk factors, since hypercholesterolemia
and diabetes could promote the expansion of HSPCs and myelopoiesis.
We have to point out that the mechanisms underlying the substantial association between CHIP
and CVD are largely unknown at the moment, and the potential mechanisms illustrated above
are hypothesis-generating. In this scenario, an intriguing possibility is that, as CHIP originates
in the HSPC compartment, resulting from HSPC clones with DNA mutations conferring them a
proliferation/survival-advantage (precancerous clonal expansion), similar mutations could influence
senescence, apoptosis and/or differentiation, resulting in dysfunctional tissue-specific adult stem cells
contributing to cardiovascular pathology and disease. Of note, the adult mammal heart harbors resident
cardiac stem/progenitor cells (CSCs) that contribute to cardiovascular pathology with age [94–96].
Thus, CHIP could influence and modulate the processes of cardiovascular tissue repair/regeneration
of the adult heart and vasculature by affecting the immune modulation of resident stem cells and
yielding a pro-fibrotic inflammatory response over reparative/regenerative tissue re-shaping. This view
widens our perspectives on the interplay between ageing, CHIP and CVD risk. In fact, ageing causes
cellular and molecular changes in tissue homeostasis, and it is associated with telomere shortening
as well as with a multi-component senescence-associated secretory phenotype (SASP), displaying
pro-inflammatory cytokines, chemokines, extracellular matrix (ECM)-degrading proteins and other
cell-cycle arrest signaling molecules [94–97]. All the above factors result in the progressive deterioration
of the structure and function of any given organ at the tissue and cell levels [97]. CSC ageing leads to a
senescent phenotype, and to a decreased ability to differentiate and to heal cardiac injuries.
Trying to translate these new discoveries into clinical practice and the reality of public health
systems worldwide, it is worth noting that in contemporary medicine, the development of new
techniques for molecular diagnosis or advancements in other diagnostic fields leads to a constantly
increasing proportion of patients who are not ill but at increased risk for specific illnesses. The number
of abnormalities increases with age (as found in CHIP). We agree that, unless there are specific practical
interventions that abrogate increased risk, the enhanced potential for diagnosis does not have an
impact on clinically meaningful endpoints. Age is the most important cardiovascular risk factor,
but the strategy to tailor therapy to the presence of CHIP is conceptual, yet still not formally proven
at the moment. Whether CHIP would be an independent predictor of risk in a multivariable model
with classical cardiovascular risk factors including age, is an open question. We can assume that there
is potential for CHIP detection as a parameter for subject stratification where CVD risk is present,
but we do not know at this stage whether knowledge of the presence of CHIP will improve therapy in
CVD patients.
In this regard, a recent publication by Sidlow and collaborators is trying to dissect and solve,
at least in part, these uncertainties: it shows, in different case stories, the ways in which clinicians might
face CHIP carriers and provide a suitable multidisciplinary protocol useful to address patients’ concerns
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in the clinical practice. This interesting and timely contribution shows three cases, ranging from
casual recognition of CHIP to a diagnosis of TET2 mutation in a screening for evaluation of a stem cell
transplant donor, to a patient treated for malignancy and in present good conditions with a somatic
JAKV621F mutation found in blood cells (for more details, see [20]).
The “take-home message” of this important contribution is that management of CHIP should
be personalized and tailored with the age and life expectancy of the patient, concurring diseases and
conditions and other CVD risk components. As witnessed by these cases, individuals with CHIP will
increasingly ask for advice from CVD specialists regarding management of the condition, and a general
suggestion can be extrapolated by this study. The challenge for practitioners is how to manage such
individuals without a solid scientific and proven scaffold. Likely, increase in genome sequencing and
increase in available data linking CHIP and CVD risk will increase the burden of guiding such patients
on clinical practitioners. Further investigation into the clinical utility of CHIP to assess CVD risk is
warranted, both in subjects who are apparently in good health status as well as in subjects with CVD
or malignant disease.
In conclusion, the research in the area of CHIP is still new and evolving, and important hallmarks
have been achieved that are beginning to clarify the role played by clonal hematopoiesis in the
cardiovascular disease setting. DNMT3A, TET2 and also JAK2 mutations may promote an enhanced
risk of CVD, but gene-specific differences could also exist and need to be fully elucidated in order
to define the best targeted therapy in the cardiovascular disciplines. It is a rapidly evolving and
promising field that nevertheless needs more experimental data and clinical studies before entering the
armamentarium of cardiology and clinical medical practice.
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CH clonal hematopoiesis
CHIP clonal hematopoiesis of indeterminate potential
CVD cardiovascular disease
DNMT3A DNA methyltransferase 3A
TET2 Tet methylcytosine dioxygenase 2
HSPC hematopoietic stem/progenitor cells
MDS myelo-dysplastic syndromes
ASXL1 additional sex combs-like transcriptional regulator 1
AML acute myeloid leukemia
TP53 tumor protein p53
JAK2 janus kinase 2
SF3B1 splicing factor 3b subunit 1
CBL casitas B-lineage lymphoma gene
SRSF2 serine and arginine rich splicing factor 2
PPM1D protein phosphatase, Mg2+/Mn2+ Dependent 1D
BCOR BCL6 Corepressor
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HF heart failure
NLRP3 NOD-, LRR- and pyrin domain-containing protein 3
CD163 Cluster Designation number 163, hemoglobin (Hb) scavenger receptor
CXCR4 C-X-C chemokine receptor type 4
CXCL12 C-X-C chemokine ligand 12
NOTCH1 Notch homolog 1, translocation-associated
MPN myeloproliferative neoplasms
NET neutrophil extracellular traps
CRP C-reactive protein
SHP2 src homology region 2 (SH2)-containing protein tyrosine phosphatase 2
STAT3 signal transducer and activator of transcription 3
CMN chronic myeloproliferative neoplasia
CSC cardiac stem/progenitors cells
SASP senescence-associated secretory phenotype
ECM extracellular matrix
CRISPR clustered regularly interspaced short palindromic repeats
hs-CRP high sensitivity C-reactive protein
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